Not checkedNot checked for notices yet.
Antibody–Drug Conjugates for Cancer Therapy
Adam C. Parslow, Sagun Parakh, Fook-Thean Lee and 2 more
Biomedicines · 2016
doi:10.3390/biomedicines4030014 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance.
Abstract licence: CC BY
References103
- 24.
Current ADC Linker Chemistry · 2015
39 more references, whose wording the paper’s licence keeps private.
All 103 referencesCited by papers we hold4
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.